Vaccine for treatment of tautopathy
AssigneesKyoto University, National Institute of Radiological Sciences
InventorsHaruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
Life of this patent
Estimating the term…
Abstract
This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.
Claims7
A vaccine for treating tauopathy dementia, comprising a vector as an active ingredient,
- wherein the vector comprises a nucleic acid encoding a full length mutant tau protein linked to a secretory signal sequence,
- wherein the full length mutant tau protein comprises a substitution mutation of an amino acid residue, P301S, at a position 301 of the amino acid sequence of SEQ ID NO:
- 1 of a tau protein, and
- wherein the vector is a Sendai virus vector and is capable of inducing an antibody to the full length mutant tau protein in a subject in a sustained manner and is capable of reacting with phosphorylated tau protein present in the hippocampus of the subject.
Dependencies are inferred from the claim text.